Unveiling the immunological terrain of pancreatic ductal adenocarcinoma: strategies to prompt immunotherapy from Mendelian randomization

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Апрель 25, 2025

Pancreatic ductal adenocarcinoma (PDAC) is challenging to treat due its immunosuppressive tumor microenvironment (TME) and resistance immune checkpoint inhibitors. This study aims discover new therapeutic targets predictive biomarkers for PDAC. Using Mendelian randomization, we studied causal relationships between PDAC an array of cell traits, bacterial inflammatory factors, blood metabolites. We employed large genome-wide association datasets the two-sample MR approach investigation. Our results highlight suggestive evidence associations distinct phenotypes, revealing nuanced alterations across monocytes, T-cells, B-cells, dendritic cells, myeloid-derived suppressor cells. provides a granular view PDAC-immune interface, identifying key traits their with For instance, our findings suggest detrimental reduction in various monocyte alongside decrease B-cell populations. Conversely, certain T-cell subsets showed increased associations, indicating potential immunotherapeutic strategies. The trait particularly Collinsella Ruminococcus torques, gut microbiome's influence on modulation pathogenesis. Additionally, concerning Interleukin-12 subunit beta levels surface glycoprotein CD5 further indicate function this complex interaction. enhances understanding PDAC's immunotherapies highlights personalized immunotherapy metabolic pathway treatment. provide supportive research clinical translation.

Язык: Английский

---

Unraveling the Microbiome’s Role in Neuroendocrine Neoplasms: A New Perspective

Neuroendocrinology, Год журнала: 2024, Номер 114(11), С. 977 - 980

Опубликована: Окт. 15, 2024

Язык: Английский

---